After molecular imaging, treatment changes were determined by assessing treatment modifications before and after SSTR-directed imaging. Change in existing CTx regimen or initiation of novel CTx, PRRT, or TKI was subsumed as systemic treatment, whereas active surveillance or RTx was classified as nonsystemic therapy.